Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion
|ClinicalTrials.gov Identifier: NCT00227136|
Recruitment Status : Terminated
First Posted : September 27, 2005
Last Update Posted : April 13, 2018
|Condition or disease||Intervention/treatment||Phase|
|Carcinoid Tumors Neuroendocrine Tumors||Drug: 5-Hydroxy-Tryptamine||Phase 3|
5-HTP is a common over the counter product that is sold in natural food stores and via the Internet. It is claimed to improve sleep problems, depression, anxiety, compulsive disorders, restless leg syndrome, migraines, fibromyalgia, and low pain threshold.Increased levels of 5-HIAA in the urine can be a of a specific type of cancer, called carcinoid tumor. Urinary 5-HIAA levels can also be increased by a number of food products and drugs. Oral 5-HTP is not known as a cause of elevation of 5-HIAA in urine. However, recent information suggests that 5-HTP may cause an increase.
In this study we examine the effect of oral 5-HTP intake (100 mg at bedtime for 10 days) on 5-HIAA excretion in the urine, following a prospective, double-blind placebo-controlled study design.
Understanding this effect may help to determine which tests should be done in a patient with increased 5-HIAA excretion who's also taking 5-HTP.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||8 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion|
|Study Start Date :||May 2005|
|Study Completion Date :||September 2005|
- Urinary excretion of 5-HIAA
- Plasma Chromogranin A
- Side effects
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00227136
|St. Joseph's Health Care|
|London, Ontario, Canada, N6A 4V2|
|Principal Investigator:||Stan HM Van Uum, MD, PhD||University of Western Ontario, Canada|